Inceptive logo

Inceptive

Emerging

Inceptive designs synthetic RNA molecules for therapeutic applications using deep learning and high-throughput experiments; targets mRNA medicines, RNA-based vaccines, and gene regulation; raised $100M Series A led by Andreessen Horowitz;

Best for: RNA Design Platform Using Deep Learning for TherapeuticsEmerging, rapid growth
Life Sciences & BioTechRNA Design Platform Using Deep Learning for TherapeuticsWebsiteUpdated May 2026

Company Overview

About Inceptive

Inceptive is a Berlin and San Francisco-based biotechnology company founded in 2021 by Jakob Uszkoreit (former senior scientist at Google Brain and co-inventor of the Transformer architecture), Rhiju Das (Stanford RNA biophysicist), and other co-founders. The company is applying deep learning to the problem of RNA design — predicting and engineering synthetic RNA sequences that fold into specific structures and perform specific biological functions, such as encoding therapeutic proteins (mRNA medicines), silencing disease genes (siRNA, antisense), or regulating cellular behavior through aptamers and riboswitches.

Business Model & Competitive Advantage

The company raised a $100M Series A led by Andreessen Horowitz Bio + Health, with additional investors including Lux Capital and GV (Google Ventures). Inceptive's approach combines large-scale experimental data generation (synthesizing and testing hundreds of thousands of RNA sequences) with deep learning models trained on the resulting structure-function datasets, creating an iterative improvement loop. The company's deep learning expertise — drawing directly from the Transformer architecture that underpins modern LLMs — is applied to learning the grammar of RNA sequence-to-structure-to-function relationships.

Competitive Landscape 2025–2026

The therapeutic RNA space has been validated at enormous scale by the success of mRNA COVID vaccines (Moderna, BioNTech) and a growing pipeline of mRNA medicines for rare diseases, cancer, and infectious diseases. However, designing RNA molecules with optimal immunogenicity profiles, stability, and protein expression levels remains an empirical challenge — one that Inceptive's AI platform is built to solve systematically. The company positions RNA as "biological software" that can be rapidly designed and reprogrammed for new therapeutic targets, with AI as the development environment.

Founded
2021
Curated content • Fact-checked and verified

Key Differentiators

Emerging Innovator

Inceptive is an emerging player bringing innovative solutions to the Life Sciences & BioTech market.

Frequently Asked Questions

Similar Brands

Neuralink logo

Neuralink

Life Sciences & BioTech
HealthtechHardwareAi PoweredB2b2cStartupDecacornNorth AmericaTechnologyPlatformEnterprise

Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with pa

Illumina logo

Illumina

Life Sciences & BioTech
B2bGlobalPublicEnterpriseHealthtechAnalyticsHardwarePlatformFortune500

Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applicat

Pliant Therapeutics logo

Pliant Therapeutics

BioTech
HealthtechTechnologyPublicB2bStartup

Pliant Therapeutics develops small molecule integrin inhibitors targeting the pathological tissue scarring (fibrosis) that drives diseases including idiopathic pulmonary fibrosis (IPF), primary sclero

Cradle logo

Cradle

Life Sciences & BioTech
HealthtechSaasNorth AmericaB2b

Cradle is a protein design platform using AI to help biotechnology and pharmaceutical companies engineer better proteins — enzymes, antibodies, and therapeutic proteins — with improved stability, acti

BioNTech logo

BioNTech

Life Sciences & BioTech
B2bGlobalPublicEnterpriseHealthtechManufacturingPlatform

BioNTech SE was founded in 2008 in Mainz, Germany by Ugur Sahin, Ozlem Tureci, and Christoph Huber with a mission to harness the immune system for individualized cancer treatment. The company pioneere

Genentech logo

Genentech

Life Sciences & BioTech
B2bGlobalEnterprisePublicHealthtechManufacturingFortune500

Genentech was founded in 1976 in South San Francisco by Herbert Boyer and Robert Swanson, becoming the first company to produce human insulin using recombinant DNA technology and essentially launching

Compare Inceptive with Competitors

Side-by-side AI visibility scores, platform breakdown, and market position.

For Inceptive

Claim This Profile

Are you from Inceptive? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.

Claim Inceptive Profile →
For competitors & analysts

Track AI Visibility in Real Time

Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Inceptive vs competitors. Get alerts when AI recommendations shift.

Start Free Tracking →